List view / Grid view
Cancer cells exhibit huge phenotypic diversity, with many well-defined phenotypes, such as invasion, deregulated proliferation and immune evasion, contributing to disease outcomes, making them uniquely amenable to phenotypic screening1...
8 June 2016 | By Dr Alexander Moscho, Bayer UK & Ireland CEO
In this opinion piece, Dr Alexander Moscho, Bayer UK & Ireland CEO, says a vote to leave the EU will deter investment and make it harder for patients to access new medicines...
31 May 2016 | By Kurt Hertogs, PhD, Head of JLINX, Johnson & Johnson Innovation
Kurt Hertogs discusses JLINX - a new initiative that aims to catalyse scientific innovation...
13 May 2016 | By Wojciech Czardybon, PhD, Project Manager, Discovery Laboratory Manager, Selvita S.A.
In this article, Wojciech Czardybon of Selvita discusses the potential of PIM/FLT3 dual inhibition in treating acute myeloid leukaemia and other cancers...
10 May 2016 | By Victoria White, Digital Content Producer
We discuss Innate Defense Regulator (IDR) technology with Soligenix's Chief Scientific Officer, Dr Oreola Donini, and find out more about SGX942...
26 April 2016 | By Victoria White, Drug Target Review
In an exclusive interview, Trevor Perrior, Research Director at Domainex, discusses the cell death regulatory protein FLIP and the potential of FLIP inhibitors as a treatment for NSCLC...
25 April 2016 | By Victoria White, Drug Target Review
We've created an infographic on the threat of antibiotic resistance, highlighting some of the recommendations made by the Review on Antimicrobial Resistance to date...
22 April 2016 | By Snehal Chougule, Allied Market Research
Here, Snehal Chougule discusses Trajan's recent investment in automation solution company, LEAP Technologies Inc...
12 April 2016 | By Caroline Richards, Editor, Drug Target Review
Here, Caroline Richards, Editor of Drug Target Review, discusses the publication and the opportunities available to authors...
31 March 2016 | By Victoria White, Drug Target Review
We asked readers of if they agreed with BIA that the UK pharmaceutical industries are stronger in the EU. The results of that poll are now in...
23 March 2016 | By Dr John Maher, Principal Investigator, National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at Guy’s and St Thomas’ and Kings College London
Here, Dr John Maher of the NIHR BRC at Guy's and St Thomas' and Kings College London discusses CAR T-cell therapy and the exciting frontier the technique has opened up in the battle against cancer...
17 March 2016 | By Drug Target Review
Included in this issue: Microfluidics, Protein Expression, Drug Targets, Biomarkers, Oncology, Assays, Antibodies, and much more...
In this Antibodies In-depth Focus: Antibody fragment technology and avian IgY antibodies: a powerful combination; plus the challenges with antibody-based targeting of VEGF...
In this Assays In-Depth Focus: "Finding a cure for neglected tropical diseases with cell-based assays", plus "The relevance of homogeneous radiometric assays in modern drug discovery"...
Long term success for pharmaceutical businesses depends upon harnessing the best tools available to bring safe and effective medicines to market at a competitive price, and to be truly successful, for such drugs to be first in class.
